Trialjectory, a New York-based AI-powered decision-support platform for patients, healthcare providers, and pharma, raised $20 million in Series A funding.

The round was led by Insight Partners, with participation from new investor JAL Ventures and from existing investors Contour Venture Partners, Rho Capital, and TIA Ventures. 

The company will use the funding to expand its operations and development efforts. Scott Barclay, Managing Director of Insight Partners. Scott will join the Trialjectory board.

Company: Trialmatch. me, Inc.

Raised: $20.0M

Round: Series A

Funding Month: February 2022

Lead Investors: Insight Partners

Additional Investors: JAL Ventures, Contour Venture Partners, Rho Capital, and TIA Ventures

Company Website: https://www.trialjectory.com/

Software Category: AI-powered decision-support platform

About the Company: Led by Tzvia Bader, Co-Founder, and CEO, Trialjectory is artificial intelligence (AI)-powered decision-support platform for cancer patients to own their treatment journey by creating a personalized treatment plan that enhances physician point of care. The SaaS Optimizer platform delivers actionable insights that directly influence trial design, improve operational processes, and marketing communication strategies while ensuring alignment with patients’ needs and expectations. Between 2019 to the end of 2021, Trialjectory’s patient community has grown to over 50,000 registered members of which, more than 40% represent diverse ethnicities that are typically underserved patient populations.

Source: https://www.finsmes.com/2022/02/trialjectory-raises-20m-in-series-a-funding.html